BiVictriX $BVX Full Year Results investegate.co.uk/bivictrix-ther… Poolbeg Pharma $POLB Results for the year ended 31 December 2022 investegate.co.uk/okyo-pharma-lt…

$BVX BiVictriX Therapeutics to "continue seeking out positive relationships" tinyurl.com/2g9ycq2x @bivictrix $BVTXF #BVX #BVTXF

2022 was a busy year for BiVictriX, as you can see from our latest Annual Report. We identified a lead for our BVX001 programme, broadened our pipeline, and expanded our scientific capabilities and premises. Read more: bivictrix.com/wp-content/upl… #drugdevelopment #pipeline #biotech

Great to see £9m MCap BiVictrix (#BVX) making progress with lead molecule testing leaving healthy bone marrow cells unharmed. Still early days and highly speculative. I hold. youtu.be/2J_FFNQcBfY

IICYMI We released our 2022 Annual Report, highlighting progress in identifying a development lead for our BVX001 programme, broadening and strengthening our pipeline, and expanding our team and labs. bivictrix.com/wp-content/upl… #drugdevelopment #drugdiscovery #biotech

Our unique Bi-Cygni® approach identifies novel pairs of antigens on cancer cells so we can create bi-specific ADCs that should be safer and more effective. Read about our latest findings in ADC Review: adcreview.com/news/bvx001-is… #ADC #antibodydiscovery #drugdevelopment #biotech

We’re delighted to announce the clinical lead for our BVX001 Bi-Cygni® CD7+CD33+ ADC for AML following significant positive in vivo results. Find out more: linkedin.com/feed/update/ur…

$BVX BiVictriX Therapeutics shares close 7% higher after making preclinical progress tinyurl.com/2n9za589 @bivictrix $BVTXF #BVX #BVTXF

$BVX BiVictriX Therapeutics data underscores the potential of leukemia drug tinyurl.com/23lbj668 @bivictrix $BVTXF #BVX #BVTXF

We’re excited to reveal the positive interim data from our second preclinical efficacy study of BVX001 — our lead ADC programme for AML - in larger tumours. Read more: bivictrix.com/news/positive-… #ADC #AML #Biotech #pipeline #antibodytherapeutics #oncology #drugdevelopment

With Cancer Immunotherapy Month coming to an end, we wanted to highlight another way we are contributing to the development of high-impact cancer therapies. Discover more about our science and pipeline: linkedin.com/feed/update/ur… #CIM23 #Immune2Cancer #immunotherapy

$BVX BiVictriX sees positive final data in BVX001 leukaemia drug study tinyurl.com/2kuo5gml @bivictrix $BVTXF #BVX #BVTXF

We’re delighted to share positive final data in the preclinical efficacy study of BVX001, our lead Bi-Cygni® bi-specific ADC for AML. Find out more: linkedin.com/feed/update/ur… #ADC #AML #pipeline #Drugdevelopment

Antibody drug conjugates: BiVictriX drives a new era in cancer medicine - zurl.co/ai4z

Discover how our clinical lead candidate, BVX001, addresses some of the shortcomings of current antibody drug conjugate (ADC) treatments for acute myeloid leukaemia in this in-depth article in Labiotech.eu labiotech.eu/in-depth/bivic… #ADC #AML #pipeline #biotech

Is the accepted dogma around the therapeutic window of #ADCs in need of a rethink? In their recent paper, Columbo and Rich highlight the mounting clinical evidence that suggests ADCs do not significantly increase the MTD of their conjugated drugs: cell.com/cancer-cell/pd…

$BVX Bivictrix Therapeutics progress attracting interest, says CEO tinyurl.com/22q2gvfu @bivictrix $BVTXF #BVX #BVTXF

We're pleased to announce our lead asset, BVX001, has been granted a US patent! This is a big step on BiVictriX's journey, providing broad protection for our lead therapeutic asset at the antigen level. Find out more: bivictrix.com/news/us-patent… #bloodcancer #AML #ADC #biotech

We’ve got MORE exciting data to share with you! 🚨 Our latest pre-clinical study found that BVX001 increased survival rates in acute myeloid leukaemia (AML) by 126% compared to an untreated control group. Find out more: bivictrix.com/news/extended-… #AML #BloodCancer #antibodies